Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial

Journal:

The Lancet Oncology

Published:

2025-05-10

DOI:

10.1016/s1470-2045(25)00190-1

Affiliations:

27

Authors:

31

Go to article

Institutions	Authors	Share
Zhongshan Hospital, Fudan University, China	3.000000	0.10
Hubei Cancer Hospital (HBCH), China	2.000000	0.07
Gansu Provincial Hospital, China	2.000000	0.07
The People's Liberation Army General Hospital (PLAGH), China	2.000000	0.07
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.03
First Affiliated Hospital, AHMU, China	1.000000	0.03
Gansu Wuwei Tumor Hospital, China	1.000000	0.03
Central Hospital of Xinxiang, China	1.000000	0.03
The Sixth People's Hospital of Shenyang, China	1.000000	0.03
Hunan Cancer Hospital, China	1.000000	0.03
Hainan General Hospital, China	1.000000	0.03
Guizhou Cancer Hospital, Guizhou Medical University, China	1.000000	0.03
Hunan Provincial People's Hospital, China	1.000000	0.03
Harbin Medical University Cancer Hospital, China	1.000000	0.03
The First Affiliated Hospital of Bengbu Medical University, China	1.000000	0.03
Jiangsu Cancer Hospital, China	1.000000	0.03
First Hospital of Lanzhou University, LZU, China	1.000000	0.03
Liaoning Cancer Hospital and Institute, China	1.000000	0.03
The First Hospital of Jilin University, China	1.000000	0.03
Nantong Tumor Hospital, China	1.000000	0.03
The First Affiliated Hospital, USTC, China	1.000000	0.03
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.03
Tangdu Hospital, China	1.000000	0.03
The First Affiliated Hospital of Guangxi Medical University, China	1.000000	0.03
Affiliated Hospital of ZMU, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?